SR ONE CAPITAL MANAGEMENT, LP
data from 30/09/2025
Capitalization
$ 691.412 M
49.86 %
Performance
$ 185.830 M
62.78 %
| Date | Ticket | Name | Weight | Capitalization | Share number | First added | Performance ($) | Performance (%) |
|---|---|---|---|---|---|---|---|---|
| 2025/09/30 | ACLX | Arcellx, Inc. | 27.86% | 192.658 M $ | 2346630 | 2022/03/31 | 38.133 M $ | 24.68 % |
| 2025/09/30 | CRSP | CRISPR Therapeutics AG | 19.11% | 132.132 M $ | 2038763 | 2024/03/31 | 16.962 M $ | 33.24 % |
| 2025/09/30 | ZBIO | Zenas BioPharma, Inc | 15.77% | 109.036 M $ | 4911539 | 2024/09/30 | 61.443 M $ | 129.10 % |
| 2025/09/30 | MLYS | Mineralys Therapeutics Inc. | 11.59% | 80.160 M $ | 2113933 | 2023/03/31 | 76.290 M $ | 180.27 % |
| 2025/09/30 | ORIC | ORIC Pharmaceuticals, Inc. | 7.84% | 54.179 M $ | 4514929 | 2025/06/30 | 8.353 M $ | 18.23 % |
| 2025/09/30 | DSGN | Design Therapeutics, Inc. | 7.11% | 49.144 M $ | 6526476 | 2021/12/31 | 27.150 M $ | 123.44 % |
| 2025/09/30 | SPRY | ARS Pharmaceuticals, Inc. | 5.83% | 40.330 M $ | 4012903 | 2022/12/31 | -29.695 M $ | -42.41 % |
| 2025/09/30 | ORKA | Oruka Therapeutics, Inc | 1.20% | 8.275 M $ | 430330 | 2024/09/30 | 3.451 M $ | 71.54 % |
| 2025/09/30 | ALMS | Alumis Inc. | 1.13% | 7.820 M $ | 1959896 | 2024/06/30 | 1.940 M $ | 33.00 % |
| 2025/09/30 | NKTX | Nkarta, Inc. | 1.00% | 6.900 M $ | 3333333 | 2022/06/30 | 1.367 M $ | 24.70 % |
| 2025/09/30 | Oculis Holding AG | 0.82% | 5.670 M $ | 322500 | 2025/03/31 | -590.175 K $ | -9.43 % | |
| 2025/09/30 | ENGN | enGene Holdings Inc. | 0.74% | 5.107 M $ | 747750 | 2024/06/30 | 2.385 M $ | 87.64 % |
| 2025/09/30 | KALA | KALA Bio, Inc. | 0.00% | 0.000 $ | 0 | 2024/06/30 | 0.000 $ | 0.00 % |